For this reason, more randomized double-blind placebo-controlled multicenter trials with appropriate doses and LAB are needed.
Numerous studies on these nutraceuticals related to cartilage degeneration reached the obvious conclusion that it is necessary to conduct more randomized double-blind, placebo-controlled trials [ 9- 11, 14- 18].
There are two more randomized, double-blind, placebo-controlled trials with omega-3 PUFA supplementation performed in patients with ICDs and at high risk of high-grade arrhythmic events.
A more recent, randomized, double-blind, sham device-controlled trial found "TOPHAT655" (a helmet-like device with lasers and light-emitting diodes) treatment to increase terminal hair count in pattern hair loss, but only male subjects were included in the trial [ 7].
40– 42 Finally, a more recent randomized, double-blind, placebo-controlled trial found that a 2-month treatment with a dietary supplement made up of P. vulgaris and Cynara scolymus extracts increased the feeling of satiation (measured by the Haber's scale for hunger/satiety scoring) in healthy overweight and obese subjects.
More recently, a randomized double-blind crossover trial demonstrated a significant reduction in insulin resistance in hypogonadal men with type 2 diabetes (55).
More recently, a randomized, double-blind, futility clinical trial of coenzyme Q10 in early PD could not reject coenzyme Q10 as futile (The NINDS NET-PD Investigators 2007).
28, 29 More recently, a randomized, double-blind study enrolling 129 T2DM patients reported that treatment with sitagliptin or glipizide monotherapy was effective and well tolerated over 54 weeks in patients with ESRD on dialysis.
More recently, two multicenter, randomized, double-blind, placebo controlled trials, one performed in the USA and the other one in Europe, both published in 2007, demonstrated that topiramate is effective and safe also in patients affected by CM, in the presence or absence of medication overuse, and/or of other migraine prophylaxis [31, 32].
More recently, a large randomized, double-blind, phase 2 gene transfer clinical trial was conducted in 74 HIV-1-infected adults who received a tat-vpr-specific anti-HIV ribozyme (OZ1) or placebo delivered in autologous CD34+ hematopoietic progenitor cells.
All acetylcholinesterase inhibitors have proved to be more effective than placebo in randomized double-blind clinical trials.
